The tweet was deleted by the author.
But we saved everything 🙂.
Allogene Therapeutics is advancing its research into allogeneic CAR T therapies through its ALPHA3 clinical trial, focusing on new treatment options for patients with large B-cell lymphoma (LBCL).
Dr. Zachary Roberts, the company’s Executive Vice President of R&D and Chief Medical Officer, recently detailed these developments during an interview with Endpoints News. The discussion emphasized the potential for off-the-shelf cell therapy to reshape treatment paradigms for LBCL, positioning Allogene Therapeutics at the forefront of innovation in cancer care.
View post on X Loading...
Allogene previously advanced its ALPHA3 trial to evaluate allogeneic CAR T cell therapy in large B-cell lymphoma patients, according to a recent update. The company also delivered its Q1 report with a focus on progress in allogeneic CAR T development, as detailed in a corporate statement. These steps reflect the firm’s ongoing commitment to advancing cell therapies.